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WHAT THIS PAPER ADDS?
 Chronic venous disease (CVD) is a signiﬁcant public health problem.
 There is a correlation between the quality of life perceived by patients with CVD and the severity of the disease objectively
evaluated by doctors.
 It is essential that doctors consider their patients’ opinions about their disease and its progress since this enables them to reinforce
their clinical decisions.a r t i c l e i n f o
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Aim: The present study aimed to demonstrate how the quality of life (QoL) perceived by patients with
chronic venous disease (CVD) is correlated with the severity of their disease objectively assessed by
primary care physician.
Material and methods: A total of 1560 patients with CVD were evaluated using four measurement
instruments: CEAP clinical classiﬁcation, Venous Clinical Severity Score (VCSS), SF-12 Health Survey and
Chronic Lower Limb Venous Insufﬁciency Questionnaire (CIVIQ-20). Statistical correlations between
these tools were analysed using Spearman’s coefﬁcient.
Results: Patients were distributed in C0, 58 (3.7%); C1, 243 (15.6%); C2, 328 (21.0%); C3, 357 (22.9%); C4,
368 (23.6%); C5, 136 (8.7%); and C6, 70 (4.5%). The VCSS score for the whole cohort was 0.89  0.53. The
correlation between CEAP and VCSS was moderately strong (r ¼ 0.69). The overall QoL scores measured
by SF and CIVIQ were 56.84  19.63 and 65.11  14.35, respectively. The correlation between the two QoL
questionnaires was very strong (r ¼ 0.81). The correlations of the SF and CIVIQ with the VCSS were
moderately strong (r ¼ 0.47 and 0.48). The correlations between QoL questionnaires and CEAP were
moderate and lower than those with VSCC.
Conclusions: While there is correlation between VCSS, CEAP, modiﬁed CIVIQ and venous ultrasound
ﬁndings, subgroup analysis indicates that this correlation is driven by different components of VCSS
compared with the other venous assessment tools. Patients’ opinions about their disease are correlated
with those assessed by primary care physicians.
 2012 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Chronic venous disease (CVD) is a well-known disorder with
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carried out in Spain,2e4 and, like other international studies, these
have drawn attention to this raised prevalence. The most recent
study reported that 71% of the Spanish population aged over 16
years has some sign or symptom of CVD, with this being serious in
49% of them.4 These high percentages have marked health-care,
human, social and economic consequences.
The different classiﬁcations of CVD have enabled an objective
approach to be taken to its various stages, resulting in less vari-
ability in epidemiological studies.5 Without doubt, some of theseed by Elsevier Ltd. All rights reserved.
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severe (cutaneous dystrophy and ulcer) grades of the syndrome to
be rigorously determined, but they do not evaluate the clinical
symptomatology in any depth or measure their impact on the
quality of life (QoL) of the patients who suffer the condition.
However, there are various QoL questionnaires (generic or
speciﬁc to venous diseases) that provide information about
patients’ perception of their own health.6 The application of these
in a number of studies has proved conclusive about the effects of
CVD on certain physical and psychic dimensions.
In this context, objective evaluation by the doctor and subjective
evaluation by the patient frame the hypothesis put forward by the
scientiﬁc societies promoting this study. Speciﬁcally, the main aim
of the study was to test whether the health-related quality of life
(HRQL) perceived by Spanish patients with CVD is directly corre-
lated with the severity of the pathology objectively assessed by
their primary care physician (PCP).
Materials and Methods
The present study is observational, cross-sectional and multi-
centre (covering the entire country). It was approved by the Sala-
manca University Hospital Scientiﬁc and Ethics Committee
(Protocol: SEA-NUL-2010-01).
Study population
The total study population comprised 1598 patients who atten-
ded a primary care consultation in which a diagnosis of CVD was
considered to be present and who had had signs or symptoms of
CVD at least 1 year before the start of study (Table 1). The diagnosis
of CVD was performed by 330 experienced PCPs in venous disease.
We used a nationally representative sample of PCPs. PCPs were
trained in CVD and have participated in several previous studies of
CVD.3 Each PCP recruited at least ﬁve patients with CVD. Thirty-
eight patients were excluded because they met one or more of the
exclusion criteria, giving a total of 1560 evaluable patients. All
included patients gave their informed consent to enter the study.
Measurement instruments used
Fourmeasurement instruments were used, two completed by the
PCPs and two completed by the patients. For eachpatient in the study,Table 1
Criteria for inclusion, exclusion and withdrawal from the study.
Inclusion criteria
Man or woman
Aged 18 years or more
Any race
Written informed consent obtained from the patient
Carrier of some sign or symptom of CVD, lasting at least 1 year
Ability to ﬁll in the quality of life questionnaires
Psychological stability and motivation in the patient
Exclusion criteria
Other severe comorbidities or signiﬁcant clinical history unrelated with CVD
Patients who are immobile
Women who are pregnant or breastfeeding
New medication for the treatment of CVD received in the previous 3 months
History of surgery or sclerotherapy in the previous 3 months
Patients who have been stressed recently (death of a loved one, serious
economic problems, etc.)
Withdrawal criteria
Questionnaire not completed (<80% items) by the researcher
C grade of CEAP not recorded by the researcher
Venous Clinical Severity Score not completed by the researcher
Quality of life questionnaires not completed by the patient
CVD ¼ Chronic Venous Disease.the PCP collected in a predetermined case report forms the presence
or absence of the following symptoms of CVD: pain or aching,
burning, swelling, sensations of heaviness, leg tiredness, muscle
cramps and/or tingling or itching. The presence of visible manifesta-
tions of venous disorders (sings)were also recorded including dilated
veins (telangiectasiae, reticular vein and varicose veins); leg oedema;
skin changes (pigmentation, eczema and lipodermatoesclerosis) or
skin changes included ulcers (healed or active). The therapeutic
history, the clinical stage of CVD (C grades of CEAP) and the Venous
Clinical Severity Score (VCSS) were obtained from all patients.
The ‘C’ of the CEAP classiﬁcation was used to categorise the
clinical features of the venous diseases.7e9 The VCSS scale was
derived directly from the CEAP clinical class; it was intended to
supplement the CEAP classiﬁcation by providing a method for
assessing the severity of CVD over time.10,11 The original VCSS
includes nine hallmarks of venous disease, each scored on
a severity scale from 0 to 3 (absent, mild, moderate and severe). The
current version of the VCSS contains an extra category for
compression. Thus, the scale can have a maximum value of 30
points. We used the mean of all 10 VCSSs.
Additionally, each patient included in the study ﬁlled in two QoL
questionnaires: the SF-12 Health Survey (a shortened form of the
SF-3612) and the Chronic Lower Limb Venous Insufﬁciency Ques-
tionnaire (CIVIQ-20).
The SF-1213 uses just 12 questions to measure functional health
andwell-being from the patient’s point of view. All scores are based
on a scale of 0e100, where 0 is the worst, and 100 is the best
possible score. The 12 scores can be aggregated into two compo-
nent scores: physical (PCS) and mental (MCS). We used the vali-
dated Spanish version of the SF-12.14
CIVIQ-20 is a QoL questionnaire speciﬁc to CVD15 comprising 20
questions and covering four QoL domains: physical, psychological,
social and pain. The CIVIQ-20 generates a score ranging from 0 to
100, with higher scores indicating better QoL. We used the vali-
dated Spanish version of the CIVIQ-20.16
Statistical analysis
The datawere collated in a PASW statistic v.18 dataﬁle. Student’s
t-test was used to test hypotheses about differences in the means.
We calculated Spearman’s rank correlation coefﬁcient between
the results of the different dimensions of the QoL scales and those
of the CEAP and VCSS questionnaires. The following general cate-
gories indicate a quick way of interpreting a calculated r-value:
0.0e0.2, very weak to negligible correlation; 0.2e0.4, weak, low
correlation (not very signiﬁcant); 0.4e0.7, moderate correlation;
0.7e0.9, strong, high correlation; 0.9e1.0, very strong correlation.17
Results
Sample
Of the 1598 patients, 1560 yielded valid results. The ﬁnal
number of PCPs participating was 312 (18 PCPs did not recruit any
patients). Patients and PCPs were distributed homogeneously
throughout Spain. The study was carried out over a period of 90
days (15 October 2010e15 January 2011).
Table 2 summarises the demographic characteristics of the
sample. The mean age of the cohort was 59 years (range, 18e99
years), the majority of which were women (74%). The mean body
mass index (BMI) was 28  2.04. Thirty-two percent of the pop-
ulation smoked, 68% had a sedentary lifestyle and 59% had
a familial history of venous disorders.
Most patients had symptoms (pain, heaviness, swelling and
cramps) with an average intensity of 2.03 (on a scale of 1e3). The
Figure 1. VCSS score (minimum ¼ 0; maximum ¼ 3) by C grade of CEAP.
Table 2
Sample characteristics (N ¼ 1560).
Attribute N %
Gender
Man 406 26.0
Women 1154 74.0
Age (years) 59.0  12.4
Height (cm) 163.4  9.8
Weight (kg) 74.5  13.1
BMI 28.3  2.04
Health behaviours
Tobacco 499 32.0
Alcohol 183 11.7
Type of work
Sedentary 1061 68.0
Non-sedentary 499 32.0
Family history of venous pathology
Yes 920 59.0
No 640 41.0
Signsa
None sign (only symptoms) 52 3.3
All types of varicose veinsb 1361 87.2
Oedema 923 59.2
Cutaneous changes without ulcer 504 32.3
Active ulcer 70 4.5
History of venous thrombosis
Deep vein thrombosis 125 8.0
Superﬁcial vein thrombosis 374 24.0
Duration of the CVI (years) 10.26  9.16
Therapeutic history
Venoactive drugs 1346 86.3
Micronized Puriﬁed Flavonoid Fraction 605 38.8
Diosmin 377 24.2
Rutine and rutosides 201 12.9
Others ecalcio dobesilate 108 6.9
Others 55 3.5
Elastic stockings 876 56.1
Sclerotherapy 75 4.8
Surgery 130 8.3
CVD ¼ Chronic Venous Disease.
a More than one sign is possible.
b Spider veins, reticular veins o varicose veins.
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presence of spider, reticular or varicose veinswas themost frequent
sign (87.2%). Seventy patients (4.5%) had active ulceration. A
previous history of superﬁcial venous thrombosis or deep vein
thrombosis was present in the 24% and 8% of patients, respectively.
The average duration of the CVD of the sample under study was
10.26 years (SD ¼ 9.16).
With respect to the therapeutic antecedents of the sample
(Table 2), it was of particular note that a pharmacological treatment
was themost often received (86.3%) and sclerotherapywas the least
used (4.8%).
C classiﬁcation of CEAP
The distribution of the series was C0, 58 (3.7%); C1, 243 (15.6%);
C2, 328 (21.0%); C3, 357 (22.9%); C4, 368 (23.6%); C5, 136 (8.7%); C6,
70 (4.5%). The majority of patients (66.5%) were in stages C2eC4.
We have included 58 patients with C0 (no venous signs of
pathology) because they presented clear symptoms of CVD.
VCSS
The mean of all 10 VCSS scores for the whole cohort was
0.89  0.53. Scores above the overall average were noted for the
attributes of pain (1.59), varicose veins (1.80), oedema (1.41) and
pigmentation (1.05). The fact that 4.5% of patients had active ulcers
means that the scores of the three items related with it (between0.19 and 0.29) were below the overall mean. The VCSS score
increased as the CEAP C grade increased. The pattern was statisti-
cally signiﬁcant (p < 0.05). The mean values of C4eCC6 were above
the average (Fig. 1).
QoL
The median was 65.11  14.35 (measured by the CIVIQ-20) and
56.84  19.63 (measured by the SF-12), the physical component
being lower (54.51) than the mental component (60.64). Both
questionnaires indicated that the QoL decreased signiﬁcantly
(p < 0.05) as the C grade of CEAP increased. This was found for all
the dimensions evaluated in the questionnaires. Grades C3eC6
were found to be below average. Grade C6 has a QoL 20 points
lower than that of grade C0 (Figs. 2 and 3).
Correlations between CEAP, VCSS and QoL (CIVIQ-20 and SF-12)
Table 3 summarises the correlations calculated. The correlation
of CEAP with VCSS was 0.690. In other words, the venous severity
score was signiﬁcantly higher in advanced venous disease. The
correlation of CIVIQ-20 with SF-12 was 0.807 (strongly positive),
indicating that higher CIVIQ-20 scores were associated with better
health-related QoL. The correlations of doctors’ evaluations of
disease severity (CEAP and VCSS) with those of the patients’
opinions of their QoL (CIVIQ-20 and SF-12) were all negative. The
correlation coefﬁcients of CEAP with CIVIQ-20 and SF-12
were 0.371 and 0.356, respectively. The correlation coefﬁcients
of VCSS with CIVIQ-20 and SF-12 were 0.481 and 0.465,
respectively. These negative correlations all indicate that increasing
disease severity is associated with reductions in QoL.
Discussion
Our results show that health-related QoL perceived by Spanish
patients with CVD is directly correlated with the severity of the
pathology objectively assessed by their PCP. In other words,
patients’ opinions about their disease are correlated with those
assessed by PCPs. The patients understood their own disease in
a proper manner and these measurements tools (CEAP, VCSS,
CIVIQ-20 and SF-12) are very useful to reinforce the clinical
decisions.
Many studies conﬁrm the enormous impacts of CVD.18e20 There
are three aspects to this: the health service, doctors and patients.
The current study attempts to provide a joint doctorepatient view.
First, we consider the doctors’ viewpoint. Several scales and scoring
systems have been described in an attempt to clarify and unify the
criteria for diagnosis, evolutionary stage and severity of the various
CVD classiﬁcations.5 We used CEAP and VCSS in our study on the
Table 3
Correlations between the dimensions of the quality of life questionnaires and CEAP
and VCSS.
CEAP VCSS
CIVIQ-20 (Pain) 0.330 0.437
CIVIQ-20 (Physical) 0.330 0.444
CIVIQ-20 (Social) 0.311 0.394
CIVIQ-20 (Psychological) 0.349 0.435
CIVIQ-20 (Total) 0.371 0.481
SF-12 (Physical Functioning) 0.341 0.407
SF-12 (Role Physical) 0.337 0.442
SF-12 (Body Pain) 0.340 0.460
SF-12 (General Health) 0.329 0.368
SF-12 (Vitality) 0.241 0.289
SF-12 (Social Functioning) 0.275 0.373
SF-12 (Role Emotional) 0.241 0.342
SF-12 (Mental Health) 0.191 0.277
SF-12 (Total Physical) 0.383 0.492
SF-12 (Total Mental) 0.264 0.355
SF-12 (Total) 0.356 0.465
CIVIQ ¼ Chronic Lower Limb Venous Insufﬁciency Questionnaire.
SF-12 ¼ Health Survey Short Form 12.
CEAP ¼ Classiﬁcation of Chronic Venous Disorders.
VCSS ¼ Venous Clinical Severity Score.
Figure 2. CIVIQ-20 score (minimum ¼ 0; maximum ¼ 100) by C grade of CEAP.
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We also consider the patients’ viewpoint. Patients’ perception of
their health, although subjective, may be objectiﬁed as a quantita-
tive value using measurement instruments at particular moments
in their life.6 The SF-36 is the most widely used generic question-
naire. We used the briefer SF-12, which has proved to be useful in
the context of CVD.21 However, studies suggest that it is preferable
to use disease-speciﬁc questionnaire, since they are more sensitive
to small but signiﬁcant variations in QoL. For this reason, we also
used the CIVIQ-20 questionnaire.22,23
Is it possible to combine these two ways of evaluating CVD?
Might the subjective feelings of the patient be correlated with the
classic criteria of the disease that doctors measure? From the
medical point of view, QoL in patients with chronic diseases, such
as CVD, is a new criterion that tells us about the true impact of the
disease on the patient and allows us to make better therapeutic
decisions.
In general, increasing disease severity is associated with
reductions in QoL.22,23 A further step included in several studies
was to examine the association of the clinical signs and symptoms
with QoL and with the eco-Doppler assessment;24 it was concluded
that the frequency of venous reﬂux increases with the CEAP C
grade. There are also publications examining the relationship
between CEAP and QoL,25,26 including some with apparently
contradictory results,27 showing no differences between the QoL of
patients with healed and active ulcers.
Our study was prompted by our observation that no researchers
had looked for correlations between CEAP, VCSS and QoL. However,
two papers have subsequently become available that cover similar
ground to our study. Carradice et al.28 examined 561 British
patients with CVD grades C2eC6 and saphenofemoral reﬂux. This
study found a relationship between the increase in clinical grade
and deterioration of QoL.Figure 3. SF-12 score (minimum ¼ 0; maximum ¼ 100) by C grade of CEAP.VCSS and its integration with other venous assessment tools
have been also previously studied. Passman et al.29 studied 2907
participants in a database of the American Venous Forum. there is
correlation between VCSS, CEAP, modiﬁed CIVIQ and venous duplex
ultrasound ﬁndings.
Comparing our study with the others mentioned above, we
note some strengths: 1) Our study is cross-sectional and does not
come from a database with the associated limitations. 2) The
number of patients evaluated in our study is quite similar to that
of previous studies. 3) Our study focusses on the correlations
between CEAP, VCSS and QoL, like that of Passman et al.;
conversely, Carradice et al. largely avoided the VCSS. 4) We used
validated and unmodiﬁed QoL questionnaires, unlike Passman
et al., who used a modiﬁed CIVIQ (with 11 items). 5) Likewise, we
used a validated Spanish version of the questionnaire speciﬁc for
CVD (CIVIQ-20), whereas Carradice et al. used another that was
more speciﬁc to varicose pathology than to CVD (Aberdeen). 6)
Our study conﬁrmed the results of the only study so far available
in which there was a good correlation between CEAP, VCSS and
QoL, with the aforementioned exception that this group used
a QoL questionnaire that has not been internationally validated. 7)
Finally, as with the British and US Studies, ours enabled CVD to be
determined for a particular population.
At the same time, we note some limitations of our study.
First, we did not carry out an eco-Doppler study. However, this
may not be too important an omission since clinical manifesta-
tions are often sufﬁcient to diagnose CVD syndrome.17 Also, the
correlation of haemodynamic data with VCSS is much weaker
than other correlated measurements.29 Second, our collaborating
physicians (the PCPs) were not specialists in venous pathology.
However, there is no reason to doubt the reliability of the data
they obtained since the PCP participants were well informed and
trained in this ﬁeld (many of them had participated in national
studies on this topic). In addition, the results of our study
corroborated that PCPs selected were good in CVD assessment
(patients’ opinions about their disease were correlated with
those assessed by PCPs).
In conclusion, there are associations between VCSS, CEAP, SF-12
and CIVIQ-20, meaning that the opinions of patients about their
disease are correlated with those detected by the doctors who treat
them. A correct assessment of the impact of disease may be accu-
rately obtained by one of the four tools studied.
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